Pharmacogenetics of nevirapine excretion into breast milk and infants' exposure through breast milk versus postexposure prophylaxis

Pharmacogenomics

Volumn 17, Issue 8, 2016, Pages 891-906

  Olagunju, Adeniyi ^a,b   Khoo, Saye ^a   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

Author keywords

breast milk; CYP2B6; infant exposure; nevirapine; pharmacokinetics

Indexed keywords

EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST MILK; CONTROLLED STUDY; CYP2B6 GENE; DRUG EXCRETION; DRUG MILK LEVEL; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MATERNAL PLASMA; MAXIMUM PLASMA CONCENTRATION; PHARMACOGENETICS; INFANT; METABOLISM; POST EXPOSURE PROPHYLAXIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTI-HIV AGENTS; HUMANS; INFANT; MILK, HUMAN; NEVIRAPINE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; POST-EXPOSURE PROPHYLAXIS;

EID: 84976521899     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs-2015-0016     Document Type: Article

References (48)

1. Ziegler JB, Cooper DA, Johnson RO, Gold J. Postnatal transmission of AIDS-associated retrovirus from mother to infant. Lancet 1(8434), 896-898 (1985).
2. Lepage P, Van De Perre P, Carael M et al. Postnatal transmission of HIV from mother to child. Lancet 2(8555), 400 (1987).
3. Dunn DT, Newell ML, Ades AE, Peckham CS. Risk of human immunodeficiency virus type 1 transmission through breastfeeding. Lancet 340(8819), 585-588 (1992).
4. Hira SK, Mangrola UG, Mwale C et al. Apparent vertical transmission of human immunodeficiency virus type 1 by breast-feeding in Zambia. J. Pediatr. 117(3), 421-424 (1990).
5. Van De Perre P, Simonon A, Hitimana DG et al. Infective and anti-infective properties of breastmilk from HIV-1-infected women. Lancet 341(8850), 914-918 (1993).
6. Milligan C, Overbaugh J. The role of cell-associated virus in mother-to-child HIV transmission. J. Infect. Dis. 210(Suppl. 3), S631-S640 (2014).
7. Sellon RK, Jordan HL, Kennedy-Stoskopf S, Tompkins MB, Tompkins WA. Feline immunodeficiency virus can be experimentally transmitted via milk during acute maternal infection. J. Virol. 68(5), 3380-3385 (1994).
8. Sagar M. Origin of the transmitted virus in HIV infection: infected cells versus cell-free virus. J. Infect. Dis. 210(Suppl. 3), S667-S673 (2014).
9. Amerongen HM, Weltzin R, Farnet CM, Michetti P, Haseltine WA, Neutra MR. Transepithelial transport of HIV-1 by intestinal M cells: a mechanism for transmission of AIDS. J. Acquir. Immune Defic. Syndr. 4(8), 760-765 (1991).
10. Bomsel M. Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier. Nat. Med. 3(1), 42-47 (1997).
11. Kramer MS, Kakuma R. The optimal duration of exclusive breastfeeding: a systematic review. Adv. Exp. Med. Biol. 554, 63-77 (2004).
12. Lallemant M, Jourdain G, Le Coeur S et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N. Engl. J. Med. 351(3), 217-228 (2004).
13. Micek MA, Dross S, Blanco AJ et al. Transmission of nevirapine-resistant HIV type 1 via breast milk to infants after single-dose nevirapine in Beira, Mozambique. J. Infect. Dis. 210, 641-645 (2014).
14. Wind-Rotolo M, Durand C, Cranmer L et al. Identification of nevirapine-resistant HIV-1 in the latent reservoir after single-dose nevirapine to prevent mother-to-child transmission of HIV-1. J. Infect. Dis. 199(9), 1301-1309 (2009).
15. WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. www.who.int
16. Permar SR, Salazar MG, Gao F et al. Clonal amplification and maternal-infant transmission of nevirapine-resistant HIV-1 variants in breast milk following single-dose nevirapine prophylaxis. Retrovirology 10, 88 (2013).
17. Jourdain G, Ngo-Giang-Huong N, Le Coeur S et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N. Engl. J. Med. 351(3), 229-240 (2004).
18. Madadi P, Koren G, Cairns J et al. Safety of codeine during breastfeeding: fatal morphine poisoning in the breastfed neonate of a mother prescribed codeine. Can. Fam. Physician 53(1), 33-35 (2007).
19. Madadi P, Shirazi F, Walter FG, Koren G. Establishing causality of CNS depression in breastfed infants following maternal codeine use. Paediatr. Drugs 10(6), 399-404 (2008).
20. Waitt CJ, Garner P, Bonnett LJ, Khoo SH, Else LJ. Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and metaanalysis of pharmacokinetic studies. J. Antimicrob. Chemother. 70(7), 1928-1941 (2015).
21. Ito S. Drug therapy for breast-feeding women. N. Engl. J. Med. 343, 118-126 (2000).
22. Olagunju A, Amara A, Waitt C et al. Validation and clinical application of a method to quantify nevirapine in dried blood spots and dried breast-milk spots. J. Antimicrob. Chemother. 70(10), 2816-2822 (2015).
23. Olagunju A, Owen A, Cressey TR. Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics 13(13), 1501-1522 (2012).
24. Siccardi M, Olagunju A, Simiele M et al. Class-specific relative genetic contribution for key antiretroviral drugs. J. Antimicrob. Chemother. 70(11), 3074-3079 (2015).
25. Liptrott NJ, Pushpakom S, Wyen C et al. Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS. Pharmacogenet. Genomics 22(1), 10-19 (2012).
26. Wyen C, Hendra H, Vogel M et al. Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J. Antimicrob. Chemother. 61(4), 914-918 (2008).
27. Calcagno A, D'Avolio A, Simiele M et al. Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. Br. J. Clin. Pharmacol. 74(1), 134-140 (2012).
28. Faucette SR, Sueyoshi T, Smith CM, Negishi M, Lecluyse EL, Wang H. Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J. Pharmacol. Exp. Ther. 317(3), 1200-1209 (2006).
29. Chen X, Pan LQ, Naranmandura H, Zeng S, Chen SQ. Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6. PLoS ONE 7(6), e38495 (2012).
30. Lamba J, Lamba V, Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics. Curr. Drug. Metab. 6(4), 369-383 (2005).
31. Swart M, Whitehorn H, Ren Y, Smith P, Ramesar RS, Dandara C. PXR and CAR single nucleotide polymorphisms influence plasma efavirenz levels in South African HIV/AIDS patients. BMC Med. Genet. 13, 112 (2012).
32. Olagunju A, Bolaji O, Amara A et al. Breast milk pharmacokinetics of efavirenz and breastfed infants' exposure in genetically defined subgroups of mother-infant pairs: an observational study. Clin. Infect. Dis. 61(3), 453-463 (2015).
33. Olagunju A, Bolaji O, Amara A et al. Pharmacogenetics of pregnancy-induced changes in efavirenz pharmacokinetics. Clin. Pharmacol. Ther. 97(3), 298-306 (2015).
34. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 169, 505-514 (2009).
35. Kromdijk W, Mulder JW, Rosing H, Smit PM, Beijnen JH, Huitema AD. Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. J. Antimicrob. Chemother. 67(5), 1211-1216 (2012).
36. Olagunju A, Bolaji OO, Amara A et al. Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. J. Antimicrob. Chemother. 70(2), 555-561 (2015).
37. Kromdijk W, Mulder JW, Rosing H, Smit PM, Beijnen JH, Huitema AD. Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. J. Antimicrob. Chemother. 67, 1211-1216 (2012).
38. Rezk NL, White N, Bridges AS et al. Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications. Ther. Drug Monit. 30(5), 611-619 (2008).
39. Mirochnick M, Thomas T, Capparelli E et al. Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy. Antimicrob. Agents Chemother. 53(3), 1170-1176 (2009).
40. Shapiro RL, Holland DT, Capparelli E et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J. Infect. Dis. 192(5), 720-727 (2005).
41. Palombi L, Pirillo MF, Andreotti M et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir. Ther. 17(8), 1511-1519 (2012).
42. Kappelhoff BS, Crommentuyn KM, De Maat MM, Mulder JW, Huitema AD, Beijnen JH. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin. Pharmacokinet. 43(13), 845-853 (2004).
43. De Vries-Sluijs TE, Dieleman JP, Arts D et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin. Pharmacokinet. 42(6), 599-605 (2003).
44. Chaix ML, Ekouevi DK, Peytavin G et al. Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected children. Antimicrob. Agents Chemother. 51(3), 896-901 (2007).
45. Acosta EP, Limoli KL, Trinh L et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob. Agents Chemother. 56, 5938-5945 (2012).
46. Fillekes Q, Mulenga V, Kabamba D et al. Pharmacokinetics of nevirapine in HIV-infected infants weighing 3 kg to less than 6 kg taking paediatric fixed dose combination tablets. AIDS 26(14), 1795-1800 (2012).
47. Mukherjee A, Singla M, Velpandian T et al. Pharmacokinetics of nevirapine, stavudine and lamivudine in Indian HIV-infected children receiving generic fixed dose combinations. Indian Pediatr. 51(3), 191-197 (2014).
48. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur. J. Biochem. 247(2), 625-634 (1997).